FMS kinase is a type III tyrosine kinase receptor that plays a central role in the
pathophysiology and management of several diseases, including a range of cancer types …

Pexidartinib, an oral small molecule inhibitor of the colony‐stimulating factor 1 receptor, is
approved for treatment of adults with symptomatic tenosynovial giant cell tumor associated …

Abstract Background and Objective Pexidartinib is a novel oral small-molecule inhibitor that
selectively targets colony-stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine …

Pexidartinib is an oral small‐molecule tyrosine kinase inhibitor that selectively targets colony‐
stimulating factor 1 receptor. Two phase 1 single‐center trials were conducted in healthy …

Pexidartinib offered a new therapeutic option for adult patients with symptomatic
tenosynovial giant cell tumor (TGCT) who were refractory to surgical treatment and had …

Pexidartinib is the first drug approved by the US Food and Drug Administration specifically to
treat the rare joint tumor tenosynovial giant cell tumor. In the current study, a validated …

Pexidartinib is a systemic treatment for patients with tenosynovial giant cell tumor not
amenable to surgery. Oral absorption of pexidartinib is affected by food; administration with …

Pexidartinib is an orally active small molecule inhibitor of tyrosine kinase. It is selective
towards the colony-stimulating factor 1 receptor (CSF1R) and has been approved by FDA for …

Pexidartinib is the first FDA approved drug for adult patients with tenosynovial giant cell
tumor that are not amenable to improvement with surgery. In vitro data has showed …